GnRH agonist trigger for final oocyte maturation is particularly important in cancer patients, in order to decrease the post-trigger estradiol exposure as well as ovarian hyperstimulation syndrome risk compared to an hCG trigger. Here, GNRH1 is linked to ovarian hyperstimulation syndrome.